Devers Shannon L.

Devers Shannon L., EVP and Chief Human Resources Officer, has demonstrated a clear selling bias in recent transactions involving Ionis Pharmaceuticals (IONS), according to SEC Form 4 filings. Since November 2025, Devers has executed 11 sales totaling approximately $8.54 million, with no corresponding purchases during this period. The most concentrated activity occurred on March 3, 2026, when Devers sold shares worth $1.59 million across three transactions—$61,031.94, $402,394.97, and $1.13 million—while also exercising options on five separate occasions totaling $726,254.35. This follows earlier disposals in January 2026, including a $783,919.68 sale on January 7 and a $634,410.35 transaction on January 16. The pattern reveals consistent divestment, with Devers liquidating holdings through both open-market sales and option exercises. Notably, the January 7 filings show a cluster of transactions where Devers sold $2.18 million in shares while acquiring $1.45 million worth through option exercises—a net reduction in exposure. The absence of any buy transactions since at least November 2025, coupled with the dollar-weighted dominance of sales (nearly double the value of buys across all reported activity), suggests a directional shift in Devers' position in IONS. All transactions relate exclusively to Ionis Pharmaceuticals, where Devers holds an executive role, with no diversification into other securities. The activity appears methodical, with multi-million-dollar disposals executed over a four-month span.